NOVEL ANTIGENS FOR THE SERODIAGNOSIS OF HUMAN BABESIOSIS

用于人类巴贝斯虫病血清学诊断的新抗原

• 批准号: 6497038
• 负责人: Raymond Houghton
• 金额: $ 13.5万
• 依托单位: CORIXA CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6497038
• 关键词: Ehrlichia; arthropod borne communicable disease; babesiosis; communicable disease diagnosis; diagnosis design /evaluation; diagnostic tests; ehrlichiosis; enzyme linked immunosorbent assay; human tissue; protozoal antigen; recombinant proteins; serology /serodiagnosis; technology /technique development; western blottings

Increase surveillance of tick-borne infections has shown that many individuals infected with Lyme disease have co-infections with Babesia microti (agent of human babesiosis) and Ehrlichia, both of which are potentially fatal in immunocompromised individuals and have been shown to impact blood transfusions. Since the treatment of B. microti infections (malaria-like intraerythrocytic parasite) is vastly different that Lyme disease there is a need for an accurate serology test to differentiate the two infections. The proposed studies will enable the development of an ELISA and Immunoblot test using B. microti recombinants in combination that will supplement the currently available Lyme disease test and eventually facilitate testing of blood donors. Development of such tests improves our ability to differentially diagnose tick-borne diseases and facilitates administration of the appropriate treatment. Advances have already been achieved at Corixa in identifying immunodominant recombinant antigens. This, in combination with collaborations with key investigators in the area of tick-borne diseases, blood banking and a leading reference laboratory for Lyme disease testing and access to their extensive serum bank should enable the goals and objectives of this proposal to be achieved. PROPOSED COMMERCIAL APPLICATION The proposed studies will lead to commercialization of diagnostic tests for use in the blood bank and reference laboratory. Such tests would provide for improved differential diagnosis of babesiosis in the presence of other tick-borne infections e.g. Lyme disease and Human Granulocytic Ehrlichiosis. The estimated market for such a test should be similar to that for Lyme disease testing both in the U.S. and worldwide. Current estimates for this market are 30-50 million dollars/year but could be greater if blood bank testing is mandated even on a regional basis.

加强对蜱传感染的监测表明，许多感染莱姆病的人同时感染了田鼠巴贝斯虫（人类巴贝斯虫病的病原体）和埃利希体，这两种病毒对于免疫功能低下的个体来说可能是致命的，并且已被证明会影响输血。由于田鼠芽孢杆菌感染（类似疟疾的红细胞内寄生虫）的治疗与莱姆病有很大不同，因此需要准确的血清学检测来区分这两种感染。 拟议的研究将能够结合使用田鼠重组体来开发 ELISA 和免疫印迹测试，这将补充目前可用的莱姆病测试，并最终促进对献血者的测试。 此类测试的开发提高了我们鉴别诊断蜱传疾病的能力，并有助于采取适当的治疗。 Corixa 在识别免疫显性重组抗原方面已经取得了进展。 再加上与蜱传疾病、血库领域的主要研究人员的合作以及莱姆病检测的领先参考实验室以及对其广泛的血清库的访问，应该能够实现该提案的目的和目标。拟议的商业应用拟议的研究将导致用于血库和参考实验室的诊断测试的商业化。 此类测试将在存在其他蜱传感染（例如蜱传感染）的情况下提供改进的巴贝斯虫病鉴别诊断。莱姆病和人类粒细胞埃利希体病。 这种测试的估计市场应该与美国和全球莱姆病测试的市场类似。 目前对该市场的估计为每年 30-5000 万美元，但如果甚至在区域范围内强制进行血库检测，则可能会更大。